lifestyle.recentlegalnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oncolytics Biotech, Inc.
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
April 27, 2026
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
April 27, 2026
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
April 6, 2026
Oncolytics Biotech® Completes Domicile Change to the United States
April 1, 2026
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
March 19, 2026
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
March 2, 2026
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
February 24, 2026
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
February 11, 2026